Newsroom

  • April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
  • March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
  • October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
  • August 27, 2012 - N30 Pharma Converts from LLC to C-Corp
  • February 21, 2012 - Board Adds Evan Loh, MD and John R. Moore

Posters

  • March 21, 2013 - S-nitrosoglutathione Reductase Inhibitors Modulate F508-del CFTR Protein Levels and Chloride Secretion In Vitro
  • March 20, 2013 - Small Molecule Inhibitors of GSNOR Possess Anti-Inflammatory and Bronchodilatory Actions in Mouse Models of Inflammatory Lung Disease and Modulate CFTR Function in F508del-CFTR Mice
  • November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
  • August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
  • July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
More posters

CF & GSNOR Inhibitors

GSNOR Inhibitors and Cystic Fibrosis

The Relevance of GSNOR Inhibitors to CF

N30 Pharma is currently evaluating its GSNOR inhibitors in a variety of in vitro and in vivo models relevant to Cystic Fibrosis.

The literature showing the potential benefits of preserving endogenous GSNO supports GSNOR inhibition as a novel therapeutic strategy for CF and is summarized as follows:

  • GSNO promotes CFTR protein expression and maturation in cells
  • GSNO stimulates chloride current in human lung epithelial cells via CFTR dependent and independent mechanisms
  • GSNO inhibits amiloride-sensitive sodium transport in rat epithelial cells that could aid in maintaining lung fluid dynamics and clearance of mucus
  • Mucociliary clearance is increased by GSNO through soluble guanylyl cyclase-cyclic guanosine monophosphate (sGC-cGMP)-mediated effects on ciliary beat frequency
  • GSNO and GSNOR inhibition relax airway smooth muscle and causes bronchodilation and, therefore, should improve lung function and clearance of viscous mucus in CF
  • Inhaled GSNO has been reported to improve oxygenation in patients with CF
  • GSNO and GSNOR inhibition exert anti-inflammatory activity via inhibition of NFκB
  • GSNOR inhibition decreased neutrophilic infiltration, and elastase-mediated lung injury in inflammatory lung disease models
GSNOR lung localization using N30 Pharma’s anti-GSNOR monoclonal antibody:
N30 Pharma - GSNOR in the lung

GSNOR in the lung